HERmark(TM) Assay Results In Metastatic Breast Cancer Presented At The San Antonio Breast Cancer Symposium

Monogram Biosciences, Inc. (Nasdaq: MGRM) presented the results of a study detailing the HERmark(TM) Assay’s ability to identify metastatic breast cancer patients who are most likely to respond to Herceptin(R). The study results were presented this week at the San Antonio Breast Cancer Symposium. [click link for full article]

More: continued here

Filed under: Breast Cancer on December 15th, 2007